New trends in cutting-edge technology, Novartis, BMS, Legend Bio and other companies CAR-T cell therapy competition ASH annual meeting; Liu Ruqian team released a new version of the gene editing system

In the coming week, the cutting-edge technology of global biomedicine has new trends:

Novartis' new-generation CAR-T therapy platform can complete therapy production in about 24 hours

·CAR-T therapy of BMS prolongs the event-free survival of patients by more than 4 times

·Long-term follow-up of Legendary Bio's CAR-T therapy showed 98% objective remission rate

·Kite and Daiichi Sankyo reached a CAR-T cell therapy authorization cooperation

·The Liu Ruqian team released a new version of the gene editing system

·Sanofi siRNA therapy reduces the annual bleeding rate by 89%

·Qilu introduced RNA interference therapy for the treatment of hepatitis B

·Focusing on RNA-targeted new drugs, Xinrui completed a seed round of US$120 million in financing

·Roche ADC portfolio reduces the risk of disease progression by 27%

· ADC Xinrui company completed 103 million US dollars in financing

Cell and gene therapy

Novartis' new-generation CAR-T therapy platform can complete therapy production in about 24 hours.
Recently, at the 63rd ASH (American Society of Hematology) annual meeting, Novartis announced the launch of a new generation of CAR-T cell therapy technology platform T-Charge
.

Sanofi siRNA therapy reduces the annual bleeding rate by 89%.
Recently, at the 63rd ASH (American Society of Hematology) annual meeting, Sanofi announced positive data from two phase III clinical trials of fitusiran
.

Roche's ADC combination reduces the risk of disease progression by 27%.
On December 14, Roche's company Genentech announced the "first-in-class" CD79b-targeting antibody conjugate (ADC) Polivy (polatuzumab vedotin), and R-CHP treatment The combination of the regimen and the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL) phase III clinical trials have obtained positive results
.